
Supplementary Online Content

Wu F, Chen B, Dong D, et al. Phase 2 evaluation of neoadjuvant intensity-modulated radiotherapy in centrally located hepatocellular carcinoma: a nonrandomized controlled trial. *JAMA Surg*. Published online October 5, 2022. doi:10.1001/jamasurg.2022.4702

eTable 1. Pattern of Recurrence

eTable 2. Acute Radiation-Related Adverse Events

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable 1. Pattern of Recurrence

Recurrence Pattern	n (%)
Total No. of cases	20 (52.6)
Early recurrence (< 2 years)	14 (36.8)
Late recurrence (≥ 2 years)	6 (15.8)
Intrahepatic recurrence†	15 (39.5)
Marginal	2 (5.3)
Non-marginal	14 (36.8)
Extrahepatic metastasis	9 (23.7)
Lung	7 (18.4)
Lymph node‡	5 (13.2)
Peritoneum	1 (2.6)
Pelvic nodule	1 (2.6)

Data are n (%). †1 case of both marginal and non-marginal recurrence; ‡3 cases of retroperitoneal lymph node metastasis, 1 case of hilar lymph node metastasis, and 1 case of mediastinal lymph node metastasis.

eTable 2. Acute Radiation-Related Adverse Events

Event	Any Grade	Grade 1	Grade 2	Grade 3
Fatigue	6 (15.8)	6 (15.8)	0	0
Nausea	3 (7.9)	3 (7.9)	0	0
Vomiting	1 (2.6)	1 (2.6)	0	0
Diarrhea	1 (2.6)	1 (2.6)	0	0
Radiodermatitis	9 (23.7)	9 (23.7)	0	0
Leukopenia	19 (50.0)	13 (34.2)	6 (15.8)	
Thrombocytopenia	13 (34.2)	7 (18.4)	5 (13.2)	1 (2.6)
Anemia	0	0	0	0
ALT increased	9 (23.7)	6 (15.8)	2 (5.3)	1 (2.6)
AST increased	14 (36.8)	12 (31.6)	1 (2.6)	1 (2.6)
Bilirubin increased	16 (42.1)	16 (42.1)	0	0
Hypoalbuminemia	5 (13.2)	5 (13.2)	0	0

Data are n (%). ALT, alanine aminotransferase; AST, aspartate aminotransferase.